Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vernakalant for acute conversion of new-onset atrial fibrillation in critically ill ICU patients
NL-OMON20722Phase 3Recruiting
- Sponsor
- Isala
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vernakalant and amiodarone in Atrial fibrillation (AFib) (4 arms), sponsored by Isala. Started May 2014; status: recruiting.
02
Drugs
vernakalantamiodarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON20722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20722.